MX2019000677A - Células miméticas de células b. - Google Patents
Células miméticas de células b.Info
- Publication number
- MX2019000677A MX2019000677A MX2019000677A MX2019000677A MX2019000677A MX 2019000677 A MX2019000677 A MX 2019000677A MX 2019000677 A MX2019000677 A MX 2019000677A MX 2019000677 A MX2019000677 A MX 2019000677A MX 2019000677 A MX2019000677 A MX 2019000677A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- mimetic
- cells
- mimetic cells
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
Abstract
La presente invención se refiere a células miméticas de células ß. Además, se proporcionan métodos para producir células miméticas de células ß así como métodos de uso de las células miméticas de células ß como un medicamento y métodos de uso de las células miméticas de células ß para la prevención, el retraso de la progresión o el tratamiento de una enfermedad metabólica en un sujeto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16180000.8A EP3272877A1 (en) | 2016-07-18 | 2016-07-18 | B-cell-mimetic cells |
EP16200258 | 2016-11-23 | ||
PCT/EP2017/067981 WO2018015330A1 (en) | 2016-07-18 | 2017-07-17 | B-cell-mimetic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000677A true MX2019000677A (es) | 2019-06-10 |
Family
ID=59564137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000677A MX2019000677A (es) | 2016-07-18 | 2017-07-17 | Células miméticas de células b. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190282710A1 (es) |
EP (1) | EP3485040B1 (es) |
JP (1) | JP2019520837A (es) |
KR (1) | KR20190026786A (es) |
CN (1) | CN109563487A (es) |
AU (1) | AU2017300590A1 (es) |
BR (1) | BR112019000837A2 (es) |
CA (1) | CA3030642A1 (es) |
IL (1) | IL264169A (es) |
MX (1) | MX2019000677A (es) |
SG (1) | SG11201811763SA (es) |
WO (1) | WO2018015330A1 (es) |
ZA (1) | ZA201900891B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116710110A (zh) * | 2020-12-28 | 2023-09-05 | 持田制药株式会社 | 新型的多层聚合物涂层交联海藻酸凝胶纤维 |
EP4268857A1 (en) * | 2020-12-28 | 2023-11-01 | Mochida Pharmaceutical Co., Ltd. | Novel multilayer polymer-coated crosslinked alginate gel fiber |
CN117042782A (zh) * | 2020-12-28 | 2023-11-10 | 持田制药株式会社 | 使用了化学交联海藻酸的多层结构体 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
EP0585368B1 (en) | 1991-04-25 | 1997-08-06 | Brown University Research Foundation | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
US5304473A (en) | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
CA2169292C (en) | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
WO1995016708A1 (en) | 1993-12-17 | 1995-06-22 | Novo Nordisk A/S | Proinsulin-like compounds |
GB9502830D0 (en) * | 1995-02-14 | 1995-04-05 | Ecole Polytech | Regulation of polypeptide production in cells |
EP0741188A3 (en) | 1995-05-05 | 1999-07-14 | Eli Lilly And Company | Single chain insulin with high bioactivity |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
WO2000004171A1 (en) * | 1998-07-15 | 2000-01-27 | Wisconsin Alumni Research Foundation | Treatment of diabetes with synthetic beta cells |
CA2403205A1 (en) * | 2000-03-13 | 2001-09-20 | Engene, Inc. | Compositions and methods of regulated protein expression in gut endocrine k cells |
KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
US7790690B2 (en) * | 2000-10-11 | 2010-09-07 | U.S. Department Of Veterans Affairs | Glucose sensitive regulator of insulin transcription |
US20030082511A1 (en) * | 2001-09-25 | 2003-05-01 | Brown Steven J. | Identification of modulatory molecules using inducible promoters |
US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
JP4294497B2 (ja) * | 2002-04-16 | 2009-07-15 | 協和発酵キリン株式会社 | 内分泌系細胞株とその利用法 |
US7312077B2 (en) * | 2002-10-02 | 2007-12-25 | Naoya Kobayashi | Insulin-secreting immortalized liver cell line modified by glucose sensitivity |
ATE517119T1 (de) | 2003-12-03 | 2011-08-15 | Novo Nordisk As | Einzelketteninsulin |
EP1863840A1 (en) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Pegylated single-chain insulin |
US20070020237A1 (en) * | 2005-06-01 | 2007-01-25 | Biotech Institute For International Innovation, Inc. | Glucose inducible insulin expression and methods of treating diabetes |
EP1991575A1 (en) | 2006-02-21 | 2008-11-19 | Novo Nordisk A/S | Single-chain insulin analogues and pharmaceutical formulations thereof |
US20090099065A1 (en) | 2006-03-13 | 2009-04-16 | Novo Nordisk A/S | Acylated Single Chain Insulin |
WO2007104737A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
WO2007104736A2 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
WO2007104734A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
CN101983066B (zh) | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | 基于酯的胰岛素前药 |
WO2009132129A2 (en) | 2008-04-22 | 2009-10-29 | Case Western Reserve University | Isoform-specific insulin analogues |
AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
CN102307584A (zh) | 2008-12-19 | 2012-01-04 | 印第安纳大学研究及科技有限公司 | 表现出对胰岛素受体的高活性的基于yl的胰岛素-样生长因子 |
US8481485B2 (en) | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
EP2616539A1 (en) * | 2010-09-15 | 2013-07-24 | Ramot at Tel-Aviv University Ltd. | Methods of expanding and redifferentiating islet beta cells |
US9265842B2 (en) * | 2010-10-15 | 2016-02-23 | Cornell University | Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders |
WO2016049031A1 (en) * | 2014-09-22 | 2016-03-31 | The Rockefeller University | Compositions and methods to modulate cell activity |
-
2017
- 2017-07-17 AU AU2017300590A patent/AU2017300590A1/en not_active Abandoned
- 2017-07-17 MX MX2019000677A patent/MX2019000677A/es unknown
- 2017-07-17 SG SG11201811763SA patent/SG11201811763SA/en unknown
- 2017-07-17 KR KR1020197002460A patent/KR20190026786A/ko active IP Right Grant
- 2017-07-17 BR BR112019000837A patent/BR112019000837A2/pt not_active Application Discontinuation
- 2017-07-17 EP EP17749378.0A patent/EP3485040B1/en active Active
- 2017-07-17 JP JP2019501949A patent/JP2019520837A/ja active Pending
- 2017-07-17 WO PCT/EP2017/067981 patent/WO2018015330A1/en unknown
- 2017-07-17 US US16/318,348 patent/US20190282710A1/en not_active Abandoned
- 2017-07-17 CA CA3030642A patent/CA3030642A1/en active Pending
- 2017-07-17 CN CN201780044279.5A patent/CN109563487A/zh active Pending
-
2019
- 2019-01-09 IL IL264169A patent/IL264169A/en unknown
- 2019-02-12 ZA ZA2019/00891A patent/ZA201900891B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20190282710A1 (en) | 2019-09-19 |
IL264169A (en) | 2019-02-28 |
EP3485040A1 (en) | 2019-05-22 |
WO2018015330A1 (en) | 2018-01-25 |
ZA201900891B (en) | 2019-12-18 |
SG11201811763SA (en) | 2019-02-27 |
AU2017300590A1 (en) | 2019-01-24 |
JP2019520837A (ja) | 2019-07-25 |
CA3030642A1 (en) | 2018-01-25 |
BR112019000837A2 (pt) | 2019-10-01 |
CN109563487A (zh) | 2019-04-02 |
EP3485040B1 (en) | 2021-04-14 |
KR20190026786A (ko) | 2019-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
WO2017030823A3 (en) | Anti-tigit antibodies | |
MX2017005834A (es) | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. | |
PH12017500153A1 (en) | Compositions and methods of use for treating metabolic disorders | |
MX2022007522A (es) | Anticuerpos anti-cd27. | |
TW201613636A (en) | Methods of treating Alzheimer's Disease | |
MX370792B (es) | Composiciones para usarse en el tratamiento de cáncer. | |
MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
WO2015120372A3 (en) | Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases | |
PH12017500120A1 (en) | Methods of improving myocardial performance in fontan patients using udenafil compositions | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
MX2019000677A (es) | Células miméticas de células b. | |
WO2015160470A3 (en) | Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease | |
PH12017501979A1 (en) | Pharmaceutical compound | |
NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
MA40574A (fr) | Traitement de maladies fibrotiques | |
IN2013MU03855A (es) | ||
MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci |